Send to

Choose Destination
Stat Biopharm Res. 2012 Jan 1;4(1):1-13.

Statistical approaches to analyzing HIV-1 neutralizing antibody assay data.

Author information

Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., Seattle, WA 98109, USA.
New York University Langone School of Medicine, Department of Pathology, New York, NY 10010, USA ; Veterans A®airs New York Harbor Healthcare System, Manhattan Campus, New York, NY 10010, USA.


Neutralizing antibody assays are widely used in research toward development of a preventive HIV-1 vaccine. Currently, the neutralization potency of an antibody is typically quantified by the inhibitory concentration (IC) values (e.g., IC50), and the neutralization breadth is estimated by the empirical method. In this paper, we propose the AUC and pAUC measures for summarizing the titration curve, which complement the commonly used IC measure. We present multiple advantages of AUC over IC50, which include no complications due to censoring, the capability to explore low-level neutralization, and improved coverage probabilities and efficiency of estimators. We also propose statistical methods for determining positive neutralization and for estimating the neutralization breadth. The simulation results suggest that the AUC measure is preferable in particular as IC50s get closer to the highest concentration of antibodies tested. For the majority of the assay data, the AUC method is more powerful than the IC50 method. However, since these methods test different hypotheses, it is not unexpected that some virus-antibody combinations are AUC positive but IC50 negative or vice versa.


AUC; HIV-1; breadth; neutralization assay; polynomial model; titration curve

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center